Literature DB >> 16876679

Incremental expenditure of treating hypertension in the United States.

Sanjeev Balu1, Joseph Thomas.   

Abstract

BACKGROUND: This study determined incremental direct expenditures of treating hypertension in the United States population.
METHODS: Analysis of the 2001 Medical Expenditure Panel Survey (MEPS), a national probability sample survey of the civilian noninstitutionalized U.S. population, was conducted. Hypertensive patients were identified as those with a medical diagnosis for hypertension based on International Classification of Diseases (ICD)-9 codes; patients who were consumers of hypertension-related medical care services including inpatient and outpatient visits, emergency room visits, home health visits, office-based medical provider visits, and other medical expenses; patients who self-reported being diagnosed with hypertension by their physicians; and patients who were prescribed antihypertensive medication. Incremental expenditure of treating hypertension was estimated through least-squares regression adjusting for age, sex, ethnicity, education, and comorbidities using the D'Hoore et al version of the Charlson comorbidity index. Sample data were projected to the U.S. population and 95% confidence limits for estimates were calculated using the Taylor expansion method.
RESULTS: Sample estimates projected to the population indicated that approximately 17.4% of individuals >or=18 years of age in the ambulatory population have hypertension. Total incremental annual direct expenditures for hypertension patients were estimated to be more than 54.0 billion US dollars in 2001 after adjusting for demographics and comorbidities. Mean incremental annual direct expenditures for an individual with hypertension was 1,131 US dollars . Prescription medicines, inpatient visits, and outpatient visits constituted >90% of overall incremental expenditures.
CONCLUSIONS: With incremental direct medical expenditures estimated at nearly 55.0 billion US dollars, hypertension expenditures represent a significant amount of health care resource use.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16876679     DOI: 10.1016/j.amjhyper.2005.12.013

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  17 in total

1.  Kidney disease and antihypertensive medication adherence: the need for improved measurement tools.

Authors:  Tara I Chang; Wolfgang C Winkelmayer
Journal:  Am J Kidney Dis       Date:  2010-09       Impact factor: 8.860

2.  Latino access to the patient-centered medical home.

Authors:  Anne Beal; Susan Hernandez; Michelle Doty
Journal:  J Gen Intern Med       Date:  2009-11       Impact factor: 5.128

3.  Hypertension-associated hospitalizations and costs in the United States, 1979-2006.

Authors:  Guijing Wang; Jing Fang; Carma Ayala
Journal:  Blood Press       Date:  2013-07-25       Impact factor: 2.835

4.  Impact of hypertension on healthcare costs among children.

Authors:  Todd P Gilmer; Patrick J O'Connor; Alan R Sinaiko; Elyse O Kharbanda; David J Magid; Nancy E Sherwood; Kenneth F Adams; Emily D Parker; Karen L Margolis
Journal:  Am J Manag Care       Date:  2014-08       Impact factor: 2.229

5.  Recent trends in healthcare utilization among children and adolescents with hypertension in the United States.

Authors:  Cheryl L Tran; Brett J Ehrmann; Kassandra L Messer; Emily Herreshoff; Amber Kroeker; Larysa Wickman; Peter Song; Nicole Kasper; Debbie S Gipson
Journal:  Hypertension       Date:  2012-06-18       Impact factor: 10.190

6.  Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece.

Authors:  Nikos Maniadakis; Mattias Ekman; Vasilios Fragoulakis; Vasiliki Papagiannopoulou; John Yfantopoulos
Journal:  Eur J Health Econ       Date:  2010-04-22

7.  Activating Patients for Sustained Chronic Disease Self-Management: Thinking Beyond Clinical Outcomes.

Authors:  Cheryl J Dye; Joel E Williams; Janet H Evatt
Journal:  J Prim Care Community Health       Date:  2016-01-20

8.  Hypertension-associated expenditures for medication among US adults.

Authors:  Guijing Wang; Lili Yan; Carma Ayala; Mary G George; Jing Fang
Journal:  Am J Hypertens       Date:  2013-05-31       Impact factor: 2.689

9.  Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial.

Authors:  Stephen G Worthley; Costas P Tsioufis; Matthew I Worthley; Ajay Sinhal; Derek P Chew; Ian T Meredith; Yuvi Malaiapan; Vasilios Papademetriou
Journal:  Eur Heart J       Date:  2013-06-19       Impact factor: 29.983

10.  Management of sacroiliac joint disruption and degenerative sacroiliitis with nonoperative care is medical resource-intensive and costly in a United States commercial payer population.

Authors:  Stacey J Ackerman; David W Polly; Tyler Knight; Tim Holt; John Cummings
Journal:  Clinicoecon Outcomes Res       Date:  2014-02-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.